NL192562B - Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. - Google Patents

Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Info

Publication number
NL192562B
NL192562B NL8301324A NL8301324A NL192562B NL 192562 B NL192562 B NL 192562B NL 8301324 A NL8301324 A NL 8301324A NL 8301324 A NL8301324 A NL 8301324A NL 192562 B NL192562 B NL 192562B
Authority
NL
Netherlands
Prior art keywords
po3h2
compound
pharmaceutical preparation
preparation containing
pharmaceutical
Prior art date
Application number
NL8301324A
Other languages
English (en)
Other versions
NL8301324A (nl
NL192562C (nl
Original Assignee
Gentili Ist Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL192562(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentili Ist Spa filed Critical Gentili Ist Spa
Publication of NL8301324A publication Critical patent/NL8301324A/nl
Publication of NL192562B publication Critical patent/NL192562B/nl
Application granted granted Critical
Publication of NL192562C publication Critical patent/NL192562C/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL8301324A 1982-04-15 1983-04-15 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. NL192562C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT2078182 1982-04-15

Publications (3)

Publication Number Publication Date
NL8301324A NL8301324A (nl) 1983-11-01
NL192562B true NL192562B (nl) 1997-06-02
NL192562C NL192562C (nl) 1997-10-03

Family

ID=11171970

Family Applications (5)

Application Number Title Priority Date Filing Date
NL8301324A NL192562C (nl) 1982-04-15 1983-04-15 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL970038C NL970038I2 (nl) 1982-04-15 1997-11-07 Farmaceutisch preparaat dat een NH2-(CH2)3-C(P03H2)2OH-verbinding bevat.
NL980004C NL980004I1 (nl) 1982-04-15 1998-01-09 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980005C NL980005I1 (nl) 1982-04-15 1998-01-26 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980010C NL980010I1 (nl) 1982-04-15 1998-03-03 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Family Applications After (4)

Application Number Title Priority Date Filing Date
NL970038C NL970038I2 (nl) 1982-04-15 1997-11-07 Farmaceutisch preparaat dat een NH2-(CH2)3-C(P03H2)2OH-verbinding bevat.
NL980004C NL980004I1 (nl) 1982-04-15 1998-01-09 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980005C NL980005I1 (nl) 1982-04-15 1998-01-26 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980010C NL980010I1 (nl) 1982-04-15 1998-03-03 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Country Status (12)

Country Link
US (1) US4621077A (nl)
JP (1) JPS58189193A (nl)
BE (1) BE896453A (nl)
CH (1) CH661437A5 (nl)
FR (1) FR2525223B1 (nl)
GB (1) GB2118042B (nl)
HK (1) HK79390A (nl)
IT (1) IT1201087B (nl)
LU (2) LU84746A1 (nl)
MX (1) MX9203428A (nl)
NL (5) NL192562C (nl)
SE (1) SE463239B (nl)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (fi) * 1989-09-08 1991-08-12 Huhtamaeki Oy Foerfarande foer framstaellning av metylenbisfosfonsyror.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) * 1990-09-18 1992-03-25 Merck & Co Inc Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
IT1247034B (it) * 1991-06-26 1994-12-12 Gentili Ist Spa Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (nl) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
EA000347B1 (ru) * 1995-02-17 1999-04-29 Мерк Энд Ко., Инк. Способ уменьшения риска невертебральных переломов костей
WO1996035407A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
AU5973496A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
JPH11506757A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 二ナトリウムアレンドロネート製剤
AU712710B2 (en) * 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
EP1007054A4 (en) * 1996-10-04 2000-07-19 Merck & Co Inc LIQUID ALENDRONATE FORMULATIONS
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6410782B1 (en) 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6416964B2 (en) 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
SI20581B (sl) 1998-08-27 2008-06-30 Teva Pharma Nove hidratne oblike natrijevega alendronata, postopki za njihovo pridobivanje in ustrezne farmacevtske učinkovine
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
HUP0200342A3 (en) * 1999-02-17 2005-02-28 Teva Pharma Novel process for preparing alendronic acid
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
SE9903345D0 (sv) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
CA2485443C (en) * 2002-05-17 2010-04-06 Teva Pharmaceutical Industries Ltd Use of aromatic hydrocarbons and silicone fluids for making bisphosphonic acids
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
SI1596870T2 (sl) * 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
US20040206932A1 (en) 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (zh) * 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
US7632098B2 (en) * 2003-08-12 2009-12-15 3M Innovative Properties Company Self-adhesive dental compositions and methods
KR20060058134A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
EP1753395B1 (en) 2004-05-24 2010-07-28 Warner Chilcott Company, LLC Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
EP1784154A1 (en) 2004-07-08 2007-05-16 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
US8722760B2 (en) 2004-08-11 2014-05-13 3M Innovative Properties Company Self-adhesive compositions including a plurality of acidic compounds
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
JP2008533173A (ja) * 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ビスホスホネート組成物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
DE112007000280A5 (de) 2006-02-03 2008-10-30 HÄRING, Thomas Phosphonsäure-haltige Blends und Phosphonsäure-haltige Polymere
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
AU2007324044A1 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Biphosphonate inhalant formulations and methods for using the same
WO2008076739A2 (en) 2006-12-13 2008-06-26 3M Innovative Properties Company Methods of using a dental composition having an acidic component and a photobleachable dye
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2711413A1 (en) * 2008-02-05 2009-08-13 Actavis Group Ptc Ehf Alendronate formulations, method of making and method of use thereof
US7964584B2 (en) * 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143123A (en) * 1966-05-18 1969-02-19 Albright & Wilson Mfg Ltd Phosphate compositions
GB1235029A (en) * 1966-12-29 1971-06-09 Procter & Gamble Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) * 1972-06-08 1976-04-13 M Francis Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) * 1972-06-30 1977-10-26 Procter & Gamble Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
GB1453667A (en) * 1973-05-23 1976-10-27 Procter & Gamble Radionuclide-labelled phosphonic acids for the treatment of calcific tumours
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
US4216211A (en) * 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) * 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (it) * 1978-06-27 1985-08-31 Gentili Ist Spa Composizione farmaceutica per la terapia dell'ittero ostruttivo non neoplastico
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
US4254114A (en) * 1979-01-02 1981-03-03 The Proctor & Gamble Company Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
GB2076889B (en) * 1980-03-12 1983-10-26 Cadbury Schweppes Transport Feeding fuel and water emulsion i c engines
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
GB2079285B (en) * 1980-07-09 1984-05-23 Symphar Sa Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) * 1980-08-27 1982-03-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) * 1980-09-29 1982-04-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (fr) * 1980-10-07 1982-03-22 Procter & Gamble Procede d'inhibition des metastases de cellules tumorales
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie

Also Published As

Publication number Publication date
NL8301324A (nl) 1983-11-01
CH661437A5 (it) 1987-07-31
NL980004I1 (nl) 1998-04-01
MX9203428A (es) 1992-07-01
NL970038I1 (nl) 1998-01-05
BE896453A (fr) 1983-08-01
NL980005I1 (nl) 1998-04-01
JPH0213645B2 (nl) 1990-04-04
FR2525223A1 (fr) 1983-10-21
US4621077A (en) 1986-11-04
GB8308791D0 (en) 1983-05-11
IT8220781A0 (it) 1982-04-15
SE463239B (sv) 1990-10-29
GB2118042B (en) 1986-01-15
LU84746A1 (fr) 1983-11-17
FR2525223B1 (fr) 1986-04-25
SE8302130D0 (sv) 1983-04-15
JPS58189193A (ja) 1983-11-04
NL970038I2 (nl) 2000-11-01
LU88714I2 (fr) 1996-08-23
SE8302130L (sv) 1983-10-16
GB2118042A (en) 1983-10-26
IT1201087B (it) 1989-01-27
NL980010I1 (nl) 1998-05-06
HK79390A (en) 1990-10-12
NL192562C (nl) 1997-10-03

Similar Documents

Publication Publication Date Title
NL980004I1 (nl) Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
DK68392A (da) Farmaceutisk praeparat indeholdende cefuroximaxetil
NO158717C (no) Dentalpreparat.
FI822005L (fi) Antifungisida aemnen, foerfarande foer deras framstaellning, och dessa innehaollande farmaceutiska sammansaettningar
IT8320789A0 (it) Procedimento per la preparazione di metilacetato.
IT8121785A0 (it) Sostanza anticoagulante.
FI834888A (fi) Gonadoliberinderivat, foerfarande foer deras framstaellning och farmaceutiska och veterinaermedicinska blandningar framstaellda daerav.
NL191754B (nl) Farmaceutisch preparaat tegen acne.
IT1197576B (it) Impianto per preparazione cartaccia
IT8324054A0 (it) Struttura per alloggiare animali.
FI823544L (fi) Triazinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar
IT8220792A0 (it) Dispositivo per la dialisi endoperitoneale.
DK534583D0 (da) Doseringspumpe
NO154544C (no) Munnpleiemiddel.
ES502892A0 (es) Un procedimiento para la preparacion de un compuesto de platino.
NL184146B (nl) Farmaceutisch preparaat dat een vinca-alkaloide bevat.
NO811003L (no) Farmasoeytiske preparater.
FI811880L (fi) Farmaceutiska bicykliska foereningar och kompositioner
IT8123204A0 (it) Procedimento per la preparazione di eteri alifatici.
IT8125157A0 (it) Procedimento per la preparazione di 2-amminoetanoli.
IT1191052B (it) Reattivo per la determinazione delle beta-lipoproteine.
IT8321066A0 (it) Procedimento per la preparazione di o-fenilendiammina.
NL182319C (nl) Bekledingspreparaat.
IT8026859A0 (it) Procedimento per la preparazione di colesterin-derivati.
IT8321807A0 (it) Procedimento per la produzione di erbicidi idrosolubili contenenti sostanze micronutritive.

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
AC1 Application for a supplementary protection certificate

Free format text: 970038, 971107

AC1 Application for a supplementary protection certificate

Free format text: 980004, 980109;980005, 980126

AC1 Application for a supplementary protection certificate

Free format text: 980010, 980303

SNR Assignments of patents or rights arising from examined patent applications

Owner name: MSD OVERSEAS MANUFACTURING CO. (IRELAND);MSD OVERS

KC1 Grant of a supplementary protection certificate

Free format text: 970038, 20030415, EXPIRES: 20080414